Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Corporate Authors:
    • Source:
      Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE
    • Publication Information:
      Publication: Baltimore, Md. : American Association for Cancer Research
      Original Publication: Chicago [etc.]
    • Subject Terms:
    • Abstract:
      Women of Latin American origin in the United States are more likely to be diagnosed with advanced breast cancer and have a higher risk of mortality than non-Hispanic White women. Studies in U.S. Latinas and Latin American women have reported a high incidence of HER2 positive (+) tumors; however, the factors contributing to this observation are unknown. Genome-wide genotype data for 1,312 patients from the Peruvian Genetics and Genomics of Breast Cancer Study (PEGEN-BC) were used to estimate genetic ancestry. We tested the association between HER2 status and genetic ancestry using logistic and multinomial logistic regression models. Findings were replicated in 616 samples from Mexico and Colombia. Average Indigenous American (IA) ancestry differed by subtype. In multivariate models, the odds of having an HER2 + tumor increased by a factor of 1.20 with every 10% increase in IA ancestry proportion (95% CI, 1.07-1.35; P = 0.001). The association between HER2 status and IA ancestry was independently replicated in samples from Mexico and Colombia. Results suggest that the high prevalence of HER2 + tumors in Latinas could be due in part to the presence of population-specific genetic variant(s) affecting HER2 expression in breast cancer. SIGNIFICANCE: The positive association between Indigenous American genetic ancestry and HER2 + breast cancer suggests that the high incidence of HER2 + subtypes in Latinas might be due to population and subtype-specific genetic risk variants.
      (©2020 American Association for Cancer Research.)
    • References:
      Proc Natl Acad Sci U S A. 2018 Jul 10;115(28):E6526-E6535. (PMID: 29946025)
      Nat Genet. 2017 Dec;49(12):1767-1778. (PMID: 29058716)
      Arch Intern Med. 2002 Sep 23;162(17):1985-93. (PMID: 12230422)
      PLoS Med. 2010 May 25;7(5):e1000279. (PMID: 20520800)
      Gigascience. 2015 Feb 25;4:7. (PMID: 25722852)
      Breast Cancer Res. 2019 Apr 3;21(1):48. (PMID: 30944014)
      Cancer Epidemiol Biomarkers Prev. 2019 Nov;28(11):1771-1783. (PMID: 31455670)
      Breast Cancer Res Treat. 2014 Apr;144(3):625-34. (PMID: 24658879)
      PLoS One. 2017 Aug 23;12(8):e0183179. (PMID: 28832682)
      Hum Mol Genet. 2012 Apr 15;21(8):1907-17. (PMID: 22228098)
      Nat Commun. 2014 Oct 20;5:5260. (PMID: 25327703)
      J Natl Cancer Inst. 1997 Sep 3;89(17):1311-2. (PMID: 9293922)
      Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23. (PMID: 12829800)
      PLoS Comput Biol. 2005 Nov;1(6):e65. (PMID: 16322765)
      CA Cancer J Clin. 2018 Nov;68(6):425-445. (PMID: 30285281)
      Crit Rev Oncol Hematol. 2010 Oct;76(1):44-52. (PMID: 19800812)
      Nat Genet. 2016 Oct;48(10):1284-1287. (PMID: 27571263)
      Breast Cancer Res. 2018 Jan 30;20(1):8. (PMID: 29382369)
      Arch Pathol Lab Med. 2016 Aug;140(8):806-14. (PMID: 27472239)
      J Womens Health (Larchmt). 2011 Oct;20(10):1543-50. (PMID: 21721934)
      Cancer Res. 2017 Jul 1;77(13):3708-3717. (PMID: 28512241)
      AJR Am J Roentgenol. 2017 Oct;209(4):920-928. (PMID: 28796549)
      PLoS One. 2018 Sep 5;13(9):e0201287. (PMID: 30183706)
      Hum Mol Genet. 2015 Dec 20;24(25):7421-31. (PMID: 26472073)
      Clin Breast Cancer. 2010 Aug 1;10(4):294-300. (PMID: 20705562)
      Cancer Epidemiol. 2015 Dec;39(6):1123-7. (PMID: 26323365)
      Pharmacogenomics. 2008 Mar;9(3):323-33. (PMID: 18303968)
      Cancer Res. 2018 Oct 15;78(20):6011-6021. (PMID: 30185547)
      Breast Cancer Res Treat. 2011 Jun;127(3):729-38. (PMID: 21076864)
      Cancer Epidemiol Biomarkers Prev. 2019 Nov;28(11):1784-1791. (PMID: 31395590)
      Breast Cancer Res Treat. 2017 Nov;166(1):185-193. (PMID: 28698973)
      PLoS Genet. 2015 Dec 04;11(12):e1005602. (PMID: 26636962)
      Breast Cancer Res Treat. 2015 Apr;150(3):655-66. (PMID: 25809092)
      Carcinogenesis. 2016 Jul;37(7):669-676. (PMID: 27207651)
      J Natl Cancer Inst. 2019 Sep 25;:. (PMID: 31553449)
      JAMA. 2015 Jan 13;313(2):165-73. (PMID: 25585328)
      Cancer Causes Control. 2014 Feb;25(2):259-65. (PMID: 24249438)
      Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):1074-82. (PMID: 20332279)
      Cancer Causes Control. 2011 Apr;22(4):553-61. (PMID: 21279543)
      Breast Cancer (Auckl). 2014 Jul 29;8:103-8. (PMID: 25125980)
      Nature. 2016 Oct 12;538(7624):161-164. (PMID: 27734877)
      Carcinogenesis. 2014 May;35(5):1012-9. (PMID: 24325915)
      Front Pharmacol. 2018 Aug 21;9:909. (PMID: 30186165)
      Cancer Epidemiol Biomarkers Prev. 2018 Jan;27(1):3-10. (PMID: 29054978)
      J Med Genet. 2010 Nov;47(11):771-4. (PMID: 20805372)
      Genome Res. 2009 Sep;19(9):1655-64. (PMID: 19648217)
      Cancer. 2012 Feb 15;118(4):908-13. (PMID: 21761402)
      CA Cancer J Clin. 2018 Nov;68(6):394-424. (PMID: 30207593)
      Cancer Res. 2008 Dec 1;68(23):9723-8. (PMID: 19047150)
      J Natl Cancer Inst. 2014 Apr 28;106(5):. (PMID: 24777111)
      Breast Cancer Res Treat. 2016 Jun;157(3):545-54. (PMID: 27220749)
      J Hum Genet. 2013 Sep;58(9):627-34. (PMID: 23863748)
      Breast J. 2009 Nov-Dec;15(6):593-602. (PMID: 19764994)
    • Grant Information:
      P50 CA093372 United States CA NCI NIH HHS; R01 CA227237 United States CA NCI NIH HHS; P30 CA033572 United States CA NCI NIH HHS; R01 CA204797 United States CA NCI NIH HHS; K24 CA169004 United States CA NCI NIH HHS; P20 CA202922 United States CA NCI NIH HHS; R01 CA184585 United States CA NCI NIH HHS
    • Accession Number:
      0 (Receptors, Estrogen)
      0 (Receptors, Progesterone)
      EC 2.7.10.1 (ERBB2 protein, human)
      EC 2.7.10.1 (Receptor, ErbB-2)
    • Publication Date:
      Date Created: 20200405 Date Completed: 20201015 Latest Revision: 20240214
    • Publication Date:
      20240214
    • Accession Number:
      PMC7202960
    • Accession Number:
      10.1158/0008-5472.CAN-19-3659
    • Accession Number:
      32245796